Learn more about our new preclinical data published in Nature, demonstrating long-term survival with genetically engineered porcine kidneys.
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants
eGenesis Announces Knut Niss as Chief Technology Officer
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model